Stoke Therapeutics, Inc. STOK NASDAQ · Healthcare · United States
$26.68 +1.83% +$0.48
Summary
38 / 100 · Bulios Score
What speaks for it
- Revenue grew by 146% a year over the last 3 years.
- It has no debt and holds $107.3M in cash.
What to watch
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- Analysts expect revenue to fall by 81% this fiscal year.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 146% a year over the last 3 years. For the next fiscal year analysts expect revenue to fall by 81%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $243.2M.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 13
- Hold 3
- Sell 0
Today's price within the analysts' price targets
The average target of $51 is 91% above today's price. 81% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- License 71%
- Service 29%
By region
The company reports no revenue by region.
License brings in 71% of revenue.
Segments in detail